CIPLA LTD vs VAIDYA SANE AYUR LAB LTD

A side-by-side comparison of CIPLA LTD (CIPLA) and VAIDYA SANE AYUR LAB LTD (MADHAVBAUG) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, CIPLA LTD leads CIPLA vs MADHAVBAUG on 9 of 14 metrics (1 tied). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

29.54
P/E ratio
23.96
3.42
P/B ratio
2.10
0.90%
Dividend yield
0.29%
₹48.02
EPS
₹8.55

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

11.60%
Return on equity
12.00%
15.00%
Return on capital
15.00%
21.00%
EBITDA margin
14.00%
13.71%
Net margin
8.41%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

7.37%
Revenue CAGR (3Y)
2.62%
10.88%
Profit CAGR (3Y)
21.64%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.15L Cr
Market cap
₹184 Cr
₹28,163 Cr
Revenue
₹107 Cr
₹3,862 Cr
Net profit
₹9 Cr
0.02
Debt / equity
0.03
CIPLA LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
  • ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.34%"]
VAIDYA SANE AYUR LAB LTD
  • + ["Company is almost debt free."]
  • ["Though the company is reporting repeated profits, it is not paying out dividend", "Company has a low return on equity of 10.2% over last 3 years.", "Working capital days have increased from 41.3 days to 112 days"]
CIPLA LTD full analysis VAIDYA SANE AYUR LAB LTD full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.